Clinical trials: Relapsed / Refractory Osteosarcoma
Osteosarcoma Recurrent, Osteosarcoma in Children
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS).
- Conditions
- Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Trial name
- NCT07144254
- Testing
- Tegavivint, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Relapsed Neuroblastoma, Refractory Neuroblastoma
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
The purpose of this study is to find the largest safe dose of i15.NKG2D.zeta-NK cells in combination with C7R.GD2.CAR-T cells, and additionally to evaluate how long they can be detected in patients' blood and what affect they…
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Trial name
- NCT07211737
- Testing
- i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Relapsed Neuroblastoma, Refractory Neuroblastoma
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma
- Trial name
- NCT03635632
- Testing
- C7R-GD2.CART cells
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- Baylor College of Medicine
Relapsed / Refractory Osteosarcoma
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma.
- Trial name
- NCT07357519
- Testing
- LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Lantheus Medical Imaging
Refractory and/or Relapsed Metastatic Solid Tumors
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk…
- Trial name
- NCT01804634
- Testing
- Cyclophosphamide, Fludarabine, low dose total body irradiation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
This is a prospective, single-center, single-arm interventional trial conducted at Tianjin Medical University Cancer Institute and Hospital.
- Trial name
- NCT07444918
- Testing
- Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Relapsed Solid Tumor, Refractory Solid Tumor
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did…
- Trial name
- NCT04238819
- Testing
- Abemaciclib, Irinotecan, Temozolomide
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Neuroblastoma, Refractory Neuroblastoma
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
The goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate in…
- Conditions
- Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma
- Trial name
- Aflac-NBL-2002 (NCT05400603)
- Testing
- Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
The purpose of this study is to determine if Magnetic Resonance guided High Intensity Focused Ultrasound ablative therapy is safe and feasible for children, adolescents, and young adults with refractory or relapsed solid tumors.
- Conditions
- Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT02076906
- Testing
- Magnetic Resonance High Intensity Focused Ultrasound
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- AeRang Kim
Osteosarcoma, Ewing Sarcoma
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2…
- Conditions
- Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor
- Trial name
- NCT05302921
- Testing
- Cryoablation Therapy, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's National Research Institute
Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.
- Conditions
- Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma
- Trial name
- NCT03458728
- Testing
- Copanlisib (BAY806946)
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Bayer
Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma
Cabozantinib With Topotecan-Cyclophosphamide
This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma.
- Conditions
- Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Trial name
- NCT04661852
- Testing
- Cabozantinib, Topotecan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Refractory or Relapsed Osteosarcoma
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed osteosarcoma.
- Trial name
- NCT01216826
- Testing
- Everolimus
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Sidnei Epelman